Holen Sie sich die Stockscreener-App
42.97
2.16%
-0.95
Handel nachbörslich:
42.97
Schlusskurs vom Vortag:
$43.92
Offen:
$44.15
24-Stunden-Volumen:
671.23K
Relative Volume:
0.59
Marktkapitalisierung:
$2.82B
Einnahmen:
$45.48M
Nettoeinkommen (Verlust:
$169.95M
KGV:
16.40
EPS:
2.62
Netto-Cashflow:
$230.85M
1W Leistung:
-5.58%
1M Leistung:
+0.94%
6M Leistung:
-7.05%
1J Leistung:
+52.00%
1-Tages-Spanne:
$42.85
$45.43
1-Wochen-Bereich:
$41.28
$45.53
52-Wochen-Spanne:
$27.00
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Vergleichen Sie PTGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
42.97 | 2.82B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics (PTGX) Reveals Promising Phase 3 Trial Results | PTGX Stock News - GuruFocus
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study - Benzinga
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study - marketscreener.com
J&J posts late-stage data for plaque psoriasis drug (JNJ:NYSE) - Seeking Alpha
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 - ACCESS Newswire
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance
Protagonist Therapeutics: Strategic Advances and Promising Pipeline Drive Buy Rating - TipRanks
Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience - insights.citeline.com
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
Protagonist Therapeutics: Q1 Earnings Snapshot - CTPost
Protagonist Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Protagonist (PTGX) Reports Q1 Revenue Below Expectations While A - GuruFocus
Protagonist (PTGX) Reports Q1 Revenue Below Expectations While Advancing Drug Pipeline | PTGX Stock News - GuruFocus
Protagonist Therapeutics, Inc SEC 10-Q Report - TradingView
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update | PTGX Stock News - GuruFocus
Protagonist Hits Major Clinical Win: Phase 3 Trial Success Sets Stage for Two FDA Filings in 2025 - Stock Titan
Envestnet Asset Management Inc. Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Mariner LLC - Defense World
Wells Fargo & Company MN Raises Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $65.44 - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Daily Progress: Protagonist Therapeutics Inc (PTGX) Drop -2.84, Closing at 44.85 - DWinneX
Bank of Montreal Can Increases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 | PTGX Stock News - GuruFocus
Protagonist Therapeutics CFO Sells Shares to Cover Tax Obligation - TradingView
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 - Eagle-Tribune
Major Clinical Breakthrough: Rusfertide Phase 3 PV Treatment Data Earns Coveted ASCO Plenary Spot - Stock Titan
Cerity Partners LLC Sells 1,185 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Legal & General Group Plc Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
When the Price of (PTGX) Talks, People Listen - news.stocktradersdaily.com
Protagonist Therapeutics Reports Granting of Inducement Award | - GuruFocus
Protagonist Therapeutics Reports Granting of Inducement Award - guardonline.com
Protagonist Awards 20,000 Stock Options to Key New Hire at $46.95 - Stock Titan
Alliancebernstein L.P. Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
The 4.2% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 558% - simplywall.st
Geode Capital Management LLC Buys 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga
Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com
BTIG maintains Buy on Protagonist Therapeutics stock, $82 target By Investing.com - Investing.com Canada
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study - Benzinga
Protagonist Therapeutics (PTGX) Unveils Promising Data for Psori - GuruFocus
Revolutionary Once-Daily Pill Achieves Complete Skin Clearance in 75% of Teen Psoriasis Patients - Stock Titan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Sei Investments Co. - Defense World
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
(PTGX) Investment Analysis - news.stocktradersdaily.com
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):